Abstract:BACKGROUNDGlioblastoma multiforme (GBM) is an aggressively malignant brain tumor known for its high recurrence rates and dismal survival outcomes. Despite advancements in surgical and therapeutic strategies, the prognosis for GBM patients remains poor. This study applies proteomic analysis to postoperative GBM tumor specimens to identify molecular markers that could enhance prognosis prediction. Through the analysis of protein expression profiles before and after tumor recurrence, we identified significant alterations in protein pathways via Gene Set Enrichment Analysis (GSEA), highlighting potential biomarkers for disease outcome prediction. METHODSWe employed Sequential Window Acquisition of All Theoretical Fragment Ion Spectra (SWATH-MS) proteomics to analyze protein samples from both primary and recurrent GBM patients. Gene Set Enrichment Analysis (GSEA) was utilized to compare protein expression profiles and discern significantly altered pathways. RESULTSAnalysis revealed 778 differentially expressed proteins (DEPs), with notable alterations in pathways such as glycolysis, interleukin signaling, and MAPK signaling. Proteins such as TOLLIP, ENO1, and ITGA2B emerged as potential prognostic markers. Validation through an online tumor prognostic analysis platform (ToPP), integrated with The Cancer Genome Atlas (TCGA) data, facilitated the development of a prognostic risk score model. This model effectively categorized patients into high and low-risk groups based on their protein expression profiles, enhancing the prediction of patient outcomes. The proteins and pathways identified offer new insights into the molecular dynamics of GBM postoperatively. The association between protein expression profiles and patient prognosis underscores the potential of these markers in developing customized therapeutic strategies. Additionally, the prognostic risk score model serves as a valuable tool for improving prognostic accuracy and could guide personalized treatment plans. CONCLUSIONProteomic profiling of GBM tumors significantly contributes to uncovering the molecular mechanisms driving this aggressive cancer and facilitates the development of dependable prognostic tools. These findings not only affirm the critical role of proteomics in cancer research but also advance personalized medicine strategies in GBM management.

Proteomic Analysis of Cerebrospinal Fluid: Toward the Identification of Biomarkers for Gliomas.

Identification of Glycoproteins in Human Cerebrospinal Fluid with a Complementary Proteomic Approach

Cnsc-08. Prognostic Biomarker Discovery Through Proteomic Analysis Of Glioblastoma Multiforme

Fingerprint pattern analysis of glioma CSF protein with mass spectrometry and its clinical significance

Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics

Mass Spectrometric Analysis of Cerebrospinal Fluid Protein for Glioma and Its Clinical Application

CSF3R as a potential prognostic biomarker and immunotherapy target in glioma

Establishment of Diagnostic Model of Cerebrospinal Protein Fingerprint Pattern for Glioma and Its Clinical Application

A Protein Microarray-Based Investigation of Cerebrospinal Fluid Reveals Distinct Autoantibody Signature in Low and High-Grade Gliomas

Comparative Proteomic Profiling Using Two-Dimensional Gel Electrophoresis and Identification via LC-MS/MS Reveals Novel Protein Biomarkers to Identify Aggressive Subtypes of WHO Grade I Meningioma

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Identification of Tumor-related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors

Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches

Bioinformatics Analysis of High-Throughput Data to Validate Potential Novel Biomarkers and Small Molecule Drugs for Glioblastoma Multiforme

Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors

Identification of serum exosomal miR-98-5p, miR-183-5p, miR-323-3p and miR-19b-3p as potential biomarkers for glioblastoma patients and investigation of their mechanisms

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Proteomics-based analysis of a pair of glioma cell lines with different tumor forming characteristics.

Proteomic analysis of meningiomas

Proteomic Identification of Potential Protein Markers in Cerebrospinal Fluid of GBS Patients

CA9, CYFIP2 and LGALS3BP—A Novel Biomarker Panel to Aid Prognostication in Glioma